BN Business News
Add your company to Business Communicator →

Zdrowie i gospodarka · 11.03.2014

Draft Guidance for Industry on Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: Developing Drug Products for Treatment; Availability

The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: Developing Drug Products for Treatment." The purpose of this draft guidance is to assist sponsors in the development of drug products for the treatment of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME).

Source: Federal Register — Food and Drug AdministrationOpen original release →